Hey folks. Though I enjoy doing these weekly reports, there is no question that there are several competing demands on my time. Creating the report spreadsheet every week is at most 10 minutes, baring a company being sold, or other unusual event. So I can keep doing that with little impact on my schedule. It’s the commentary that takes up most of the time.
With all the gyrations in the market, ending in the red for the week, (NASDAQ Composite off -1.1%) it seemed that the biotechs looked more even keeled, at least as measured by the composites’ performance. This is not to say there wasn’t some excitement. After three straight weeks in the number one spot, NVAX didn’t make the top five, supplanted by INSM (+107% of its initial value) based on good clinical trial results and a public placement of $650 million priced at 90% of the week’s closing price (but more than 95% higher than it started out with.)
finance.yahoo.com
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Australian biotech provided the next two winners of the week, CU6.AX (+38%) and TLX.AX (+25%) the latter posting some positive results on a prostate cancer therapy. This pushed CU6.AX into the number four spot (+160%) n the YTD standings. JSPR, in fourth (+26%), pushed past NVAX into the number two spot (+230%).
The average portfolio took another (smaller hit), dropping $410 this week, though the YTD is still in the black.
Given that BULBAMAN is the only contestant with money on the Australians, plus a holding in LRMR (fifth best performer for the week, +20%) it is no surprise that they took the number one spot for this week, +$12.4k, which in turn upped their number one YTD return to +$78k. ERIKOTTO is the only holder of INSM, which put them at +$11.6 for the week, not that far behind BULBAMAN, and enough to move past TOMATO and BLADERUNNER into the number two YTD spot at +$32k, which was a great result. But now number two means $46k behind BULBAMAN, one of the largest leads of the year, TECHNETIUM’s median weekly performance (-$1.9k) but they are still (barely) in the black YTD and back in the winner’s list at 8th, (+$1.8k)
Report Time Ranges
|
|
|
|
|
| From
| To
|
|
|
|
|
|
|
|
| Recent
| 5/24/24
| 5/31/24
|
|
|
|
|
|
|
|
| YTD
| 12/31/2023
|
|
|
|
| Index Portfolios’ Performance
|
|
|
|
| Symbol
| Recent P/L
| Recent %
| YTD P/L
|
|
|
|
|
|
|
|
| ^IXIC
| -$1,237.59
| -1.1%
| $11,482.40
|
|
|
|
|
|
|
|
| ^NBI
| -$434.01
| -0.4%
| $698.14
|
|
|
|
|
|
|
|
| ^SPSIBI
| $178.44
| 0.2%
| -$344.66
|
|
|
|
| Share Performance
| Recent Performance
| YTD Performance
|
| Top Five
|
| Bottom Five
|
| Top Five
|
| Bottom 5
| Symbol
| P/L / Initial Price
| Symbol
| P/L / Initial Price
| Symbol
| YTD P/L / Initial Price
| Symbol
| YTD P/L/ Initial Price
| INSM
| 106.6%
| VERU
| -30.6%
| VKTX
| 234.6%
| GLYC
| -88.5%
| CU6.AX
| 38.4%
| GTHX
| -25.9%
| JSPR
| 229.0%
| AMLX
| -88.3%
| TLX.AX
| 26.5%
| MRNA
| -24.2%
| NVAX
| 213.1%
| CNSP
| -83.0%
| JSPR
| 25.9%
| CRDF
| -17.6%
| CU6.AX
| 161.2%
| PACB
| -81.8%
| LRMR
| 20.2%
| IOVA
| -13.9%
| CRDF
| 114.9%
| RVNC
| -67.7%
| Average and Median Portfolio Performance
|
| Recent P/L
|
|
|
| YTD P/L
|
|
|
| Avg.
| Median
|
|
|
| Avg
| Median
|
|
|
| -$413.48
| -$1,897.78
| TECHNETIUM
|
| $6,036.38
| -$1,149.91
| STEVE LOKNESS
| Top Seven Portfolio Performances
| Top Recent Performers
| Top YTD Performers
| Contestant (Prev. Rank)
| Recent P/L
| P/L vs. ^SPSIBI
| YTD P/L (Rank)
| Contestant (Prev. Rank)
| YTD P/L
| vs. Top Portfolio
| P/L vs. ^SPSIBI
| Rec. P/L (Rank)
| 1 - BULBAMAN (6)
| $12,421.41
| $12,242.97
| $78,261.98 (1)
| 1 - BULBAMAN (1)
| $78,261.98
| ——
| $78,606.64
| $12,421.41 (1)
| 2 - ERIKOTTO (13)
| $11,664.70
| $11,486.26
| $32,382.51 (2)
| 2 - ERIKOTTO (4)
| $32,382.51
| $45,879.47
| $32,727.17
| $11,664.70 (2)
| 3 - ARTHUR RADLEY (14)
| $2,340.90
| $2,162.46
| -$20,403.52 (16)
| 3 - BLADERUNNER (2)
| $31,800.56
| $46,461.42
| $32,145.22
| -$4,532.74 (16)
| 4 - ALONER (8)
| $192.23
| $13.79
| -$9,982.30 (14)
| 4 - TOMATO (3)
| $27,150.32
| $51,111.66
| $27,494.98
| -$1,963.53 (10)
| 5 - KATHLEEN (16)
| $114.14
| -$64.30
| -$3,780.12 (11)
| 5 - JACK HARTMANN (5)
| $8,435.05
| $69,826.93
| $8,779.71
| -$4,179.05 (15)
| 6 - DEW_DILIGENCE (3)
| -$637.73
| -$816.18
| $7,585.65 (6)
| 6 - DEW_DILIGENCE (6)
| $7,585.65
| $70,676.33
| $7,930.31
| -$637.73 (6)
| 7 - A. J. MULLEN (7)
| -$1,077.48
| -$1,255.92
| -$25,005.11 (17)
| 7 - RAJU_BIJLEE (7)
| $4,902.75
| $73,359.23
| $5,247.41
| -$2,625.15 (12)
| 8 - JR_95 (12)
| -$1,811.85
| -$1,990.29
| -$19,451.65 (15)
| 8 - TECHNETIUM (9)
| $1,872.29
| $76,389.69
| $2,216.95
| -$1,897.78 (9)
| Top Portfolios’ Contents
| Second Place Recent Performance Portfolio (ERIKOTTO)
| Top YTD Performance Portfolio (BULBAMAN)
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| Symbol (Rank)
| Initial Allocation
| Value/Total | ROI
| YTD Stock P/L
| Recent Stock P/L
| % Current Price Change for $1,000 P/L
| GLTO
| 10.00%
| 6.4% | -15.6%
| -$1,555.56
| -$304.17
| 11.8%
| CU6.AX
| 20.00%
| 29.3% | 161.2%
| $32,242.36
| $7,670.42
| 1.9%
| INSM
| 10.00%
| 13.4% | 77.6%
| $7,763.79
| $10,664.73
| 5.6%
| CYTH
| 10.00%
| 4.5% | -19.5%
| -$1,949.69
| -$440.25
| 12.4%
| LIFE
| 15.00%
| 13.9% | 22.7%
| $3,404.26
| -$744.68
| 5.4%
| LRMR
| 10.00%
| 9.9% | 75.8%
| $7,582.42
| $2,021.98
| 5.7%
| LRMR
| 15.00%
| 19.9% | 75.8%
| $11,373.63
| $3,032.97
| 3.8%
| PMN
| 10.00%
| 9.0% | 60.2%
| $6,017.39
| $843.48
| 6.2%
| OCUL
| 15.00%
| 14.5% | 27.8%
| $4,170.40
| -$319.51
| 5.2%
| SNGX
| 10.00%
| 2.3% | -58.6%
| -$5,855.26
| -$657.89
| 24.1%
| PYXS
| 5.00%
| 7.8% | 107.8%
| $5,388.89
| -$194.44
| 9.6%
| TCON
| 10.00%
| 2.1% | -63.4%
| -$6,344.95
| -$599.66
| 27.4%
| SERA
| 5.00%
| 5.7% | 50.5%
| $2,525.08
| $292.64
| 13.3%
| TLX.AX
| 15.00%
| 14.8% | 75.9%
| $11,387.00
| $3,978.29
| 3.8%
| TNYA
| 10.00%
| 9.8% | 29.9%
| $2,993.83
| -$1,018.52
| 7.7%
| VKTX
| 15.00%
| 28.2% | 234.6%
| $35,182.70
| -$394.95
| 2.0%
| TPST
| 15.00%
| 8.5% | -24.5%
| -$3,681.82
| $255.68
| 8.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and a lot of analyst chatter. |
